Clinical Trial Update: Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating tenofovir alafenamide (TAF) to prevent mother-to-child transmission of Hepatitis B virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Mother to Child Transmission

Drugs mentioned

• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hepatitis B, Chronic, Mother to Child Transmission | Phase 4 | Status: UNKNOWN